Sparfloxacin vs. Levofloxacin for Urinary Tract Infection: Clinical Observation
Abstract
OBJECTIVE: To study the clinical efficacy and safety of Sparfloxacin vs.Levofloxacin in the treatment of simple urinary tract infection.METHODS: A total of 86 patients with simple urinary tract infection were enrolled in this randomized controlled trial: the trial group(group A,n=44) were assigned to orally take Sparfloxacin qd for 7d,and the control group(group B,n=42) to orally take levofloxacin 200mg bid for 7d.RESULTS: Numbers of cases with recovery,excellent efficacy,improvement,and inefficacy and the effective rate,recovery rate,and clearance rate of bacteria in group A were 26,13,4,1,88.64%,59.1%,and 86.5.0%,respectively,and those for group B were 24,12,4,2,85.71%,57.1%,and 85.2%,respectively.There were no significant differences between two groups(P0.05).The incidences of adverse effects of group A vs.group B were 11.36% vs.9.52%(P0.05).CONCLUSION: Sparfloxacin is effective for simple urinary tract infection with curative efficacy and safety similar to those of levofloxacin.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 86 participants or records.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.